Patients with Sjögren’s syndrome and Behçet’s disease have a significantly higher risk of developing obstructive sleep apnea compared to people without those autoimmune disorders, a study has found. The study, “Risk of Obstructive Sleep Apnea in Patients with Sjögren Syndrome and Behçet’s Disease: A Nationwide, Population-Based…
News
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
Many people with Sjögren’s syndrome experience oral symptoms beyond mouth dryness — with trouble in speaking, oral ulcers, and difficulty swallowing identified as the ones that most impact their quality of life and finances — a study based on a U.S. patient survey has found. The study was presented…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
A new machine learning algorithm may help identify people with primary Sjögren’s syndrome who are at an increased risk of developing non-Hodgkin’s lymphoma (NHL), a type of blood cancer, findings from a new study suggest. Using risk features such as enlarged salivary glands, counts of certain types of…
Sjogren’s syndrome is an autoimmune disease characterized by a decreased production of saliva, tears, and other secretions. A common symptom of Sjogren’s syndrome is acid reflux, also known as gastric reflux or heartburn. Sometimes, gastric reflux may progress into a more serious condition called gastroesophageal reflux…
A Phase 4 clinical trial investigating LO2A eye drops, by Wize Pharma, as a treatment for dry eye symptoms in Sjögren’s syndrome patients is fully enrolled, the company announced. Topline results from the study, taking place at multiple sites in Israel, are expected by August. They will be used to…
LOU064, an inhibitor of the Bruton tyrosine kinase (BTK) protein, is able to reduce the activation of B-cells both in lab dishes and in animal models, suggesting it has therapeutic potential in diseases such as Sjögren’s syndrome, a study shows. These findings were further confirmed in healthy volunteers,…
Alpine Immune Sciences‘ ALPN-101, a treatment for inflammatory and autoimmune diseases that works by inhibiting two key pathways — ICOS and CD38 — is better at reducing immune cell activity than a combination of treatments targeting these molecules individually, suggests a study in cells and animal models of Sjögren’s…
Sjögren’s syndrome can be classified into four distinct groups based on symptoms, and these groupings may be suggestive of differences in underlying biology and even response to treatment, a new study suggests. The study, “Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international…
Recent Posts
- Efgartigimod shows signals of benefit in Sjögren’s disease clinical trial
- Sjögren’s symptoms differ by sex, but overall impact similar
- Sjögren’s symptoms extend far beyond dryness, U.S. survey finds
- Study links anti-Ro antibody patterns to disease features in Sjögren’s
- Global trial of telitacicept for Sjögren’s doses first patient ‘within weeks’
- Patients, advocates working this month to raise awareness of Sjögren’s
- Biotech, US university partner on new ways to speed Sjögren’s diagnosis
- New study links alternative splicing patterns to Sjögren’s severity
- Initial data from trial testing CLN-978 in Sjögren’s expected this year
- Sjögren’s disease may increase risk of certain digestive cancers: Korean study